No black box warning on record for Rebinyn

As of the latest FDA labeling reviewed, Rebinyn (COAGULATION FACTOR IX RECOMBINANT, GLYCOPEGYLATED) does not carry a black box warning. Standard warnings and precautions still apply — see the full Rebinyn medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Hypersensitivity reactions, including anaphylaxis, have occurred. Should hypersensitivity reactions occur, discontinue REBINYN and administer appropriate treatment ( 5.1 ). • Neutralizing antibodies (inhibitors) to Factor IX have occurred following administration of REBINYN. Perform an assay that measures Factor IX inhibitor concentration if bleeding is not controlled

No black box warning on record for Rebinyn

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Hypersensitivity reactions, including anaphylaxis, have occurred. Should hypersensitivity reactions occur, discontinue REBINYN and administer appropriate treatment ( 5.1 ). • Neutralizing antibodies (inhibitors) to Factor IX have occurred following administration of REBINYN. Perform an assay that measures Factor IX inhibitor concentration if bleeding is not controlled

Rebinyn Black Box Warning

No black box warning on record for Rebinyn

Other warnings & precautions

Rebinyn Black Box Warning

No black box warning on record for Rebinyn

Other warnings & precautions